Investors & Media

Company Profile
We are the leading company in RNA-targeted drug discovery and development with a pipeline of first-in-class or best-in-class medicines with the potential to provide high value for patients with significant unmet medical needs. We have created an efficient and broadly applicable drug discovery platform. Using this platform, we believe that we are revolutionizing medicine with the goal to improve the quality of, and save, lives.
Recent Press ReleasesMore >>
08/22/16Ionis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives E. B. Hershberg Award from the American Chemical Society
CARLSBAD, Calif., Aug. 22, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that Stanley T. Crooke, Ph.D., M.D., founder, CEO and chairman of the board of directors of Ionis Pharmaceuticals, Inc., has been awarded the E. B. Hershberg Award for important discoveries in medicinally active substances by the American Chemical Society, a society representing more than 150,000 scientists.  The E. B. Hershberg Award recognizes Dr. Crooke's achievements in leading the crea... 
Printer Friendly Version
08/09/16Ionis Pharmaceuticals Reports Financial Results and Highlights for Second Quarter 2016
Conference Call Webcast Tuesday, August 9, 11:30 a.m. ET at CARLSBAD, Calif., Aug. 9, 2016 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported that its financial results for the first half of 2016 were in line with the Company's expectations and the Company is on track to meet its pro forma NOL and cash guidance for the year. "The recent announcement to file for regulatory approval of nusinersen based on positive results from an interim analysis ... 
Printer Friendly Version
08/01/16Biogen and Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular Atrophy
— Biogen Intends to File Marketing Applications for Nusinersen with Regulatory Authorities in the Coming Months — — Biogen Exercises Option to Develop and Commercialize Nusinersen Globally — — Companies to Host Webcast Today at 9:00 a.m. EDT to Provide Program Update — CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Aug. 1, 2016-- Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS) today announced that nusinersen, their investigational treatment for spinal muscular atrophy (... 
Printer Friendly Version
07/28/16Akcea Therapeutics Receives Orphan Designation in Europe for Volanesorsen for the Treatment of Familial Partial Lipodystrophy (FPL)
CAMBRIDGE, Mass., July 28, 2016 /PRNewswire/ -- Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today that the European Commission (EC) has designated volanesorsen as an orphan medicinal product for the treatment of familial partial lipodystrophy (FPL).  FPL is a rare lipid disorder characterized by abnormal fat distribution across the body and a range of metabolic abnormalities, including severe type 2 diabetes, high triglycerides, and accu... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.

For more information requests, please visit our Information Request page.

If you are interested in Ionis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.

Data provided by Nasdaq. Minimum 15 minutes delayed.